Sinecod syrup

Land: Armenia

Språk: engelsk

Kilde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktiv ingrediens:

butamirate (butamirate citrate)

Tilgjengelig fra:

GlaxoSmithKline Consumer Healthcare S.A.

ATC-kode:

R05DB13

INN (International Name):

butamirate (butamirate citrate)

Dosering :

1,5mg/ml

Legemiddelform:

syrup

Enheter i pakken:

glass bottle 200ml and measuring cup

Resept typen:

OTC

Autorisasjon status:

Registered

Autorisasjon dato:

2019-03-25

Preparatomtale

Novartis Consumer Health SA
CH-1260 Nyon, Switzerland
Global Regulatory Affairs
Global Labelling & Compliance
SINECOD
®
syrup
Butamirate citrate
CORE SUMMARY OF PRODUCT CHARACTERISTICS (SMPC)
Author(s):
Jean-Michel Casado, Helena Beauvallon
Document status:
FINAL
GLC approval date:
11 Jun 2009
GLC tracking ID:
Amendment date(s):
Release date:
Next update date:
Jun 2014
Number of pages:
7
Property of Novartis
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis
Novartis Consumer Health SA
CONFIDENTIAL
Page 2
Core SmPC
GLC: 11 Jun 2009
Sinecod
1
NAME OF THE MEDICINAL PRODUCT
.......................................................................
3
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
............................................. 3
3
PHARMACEUTICAL FORM
............................................................................................
3
4
CLINICAL PARTICULARS
..............................................................................................
3
4.1
Therapeutic indications
............................................................................................
3
4.2
Posology and method of administration
.................................................................. 3
4.3
Contraindications
.....................................................................................................
3
4.4
Special warnings and precautions for use
................................................................ 3
4.5
Interaction with other medicinal products and other forms of
interaction .............. 4
4.6
Pregnancy and lactation
...........................................................................................
4
4.7
Effects on ability to drive and use machines
........................................................... 4
4.8
Undesirable effects
..................................................................................................
4
4.9
Overdose
............................................................................